Spirea
8 employees on LinkedIn · 9 known investors
Find your way into Spirea
Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases. The company develops proprietary linker-payloads and offers ADC design and conjugation expertise for partnering with pharmaceutical and biotech companies.
Founders & leadership
Investors · 9
Cambridge Angels groupCambridge · $195K – $1.9M
Start CodonCambridge
ACF Investorsreported · 2 sourcesSheffield · $125K – $1.3M
O2h Venturesreported · 2 sourcesCambridge
R42 Groupreported · 2 sourcesSan Francisco
Also in the syndicate · 4
Cambridge AngelsCambridge EnterpriseleadJonathan MilnerleadSyndicate Room
Funding
SEC filings, press & company announcements- Undisclosed amountseed fundingDec 2020
o2h ventures (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Spirea do?
- Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases. The company develops proprietary linker-payloads and offers ADC design and conjugation expertise for partnering with pharmaceutical and biotech companies.
- Who founded Spirea?
- Spirea was founded by Myriam Ouberai.
- Who are Spirea's investors?
- Spirea's investors include Cambridge Angels group, Start Codon, ACF Investors, O2h Ventures, R42 Group.